Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: A phase II trial
Open Access
- 1 November 1999
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 10 (11) , 1307-1310
- https://doi.org/10.1023/a:1008315106697
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997
- How Much Can We Rely on the Level of Prostate-Specific Antigen as an End Point for Evaluation of Clinical Trials? A Word of Caution!JNCI Journal of the National Cancer Institute, 1996
- Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.Journal of Clinical Oncology, 1996
- Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patientsCancer, 1996
- Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.Journal of Clinical Oncology, 1994
- Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer.Journal of Clinical Oncology, 1992
- Methods for Measuring Clinical Pain in HumansActa Anaesthesiologica Scandinavica, 1982